From the Department of Biological Chemistry, The
Institute of Life Sciences, The Wolfson Centre for Applied Structural
Biology, The Hebrew University of Jerusalem, Givat Ram, Jerusalem
91904, Israel and the § Department of Biological Chemistry,
The Weizmann Institute of Science, Rehovot 76100, Israel
Received for publication, September 30, 2002, and in revised form, December 17, 2002
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Introduction of enzymatic activity into proteins
or other types of polymers by rational design is a major objective in
the life sciences. To date, relatively low levels of enzymatic activity could be introduced into antibodies by using transition-state analogues
of haptens. In the present study, we identify the structural elements
that contribute to the observed hydrolytic activity in egg white
avidin, which promote the cleavage of active biotin esters (notably
biotinyl p-nitrophenyl ester). The latter elements were
then incorporated into bacterial streptavidin via genetic engineering.
The streptavidin molecule was thus converted from a protector to an
enhancer of hydrolysis of biotin esters. The conversion was
accomplished by the combined replacement of a "lid-like loop"
(L3,4) and a leucine-to-arginine point mutation in streptavidin. Interestingly, neither of these elements play a direct role
in the hydrolytic reaction. The latter features were thus shown to be
responsible for enhanced substrate hydrolysis. This work indicates that
structural and non-catalytic elements of a protein can be modified to
promote the induced fit of a substrate for subsequent interaction with
either a catalytic residue or water molecules. This approach
complements the conventional design of active sites that involves
direct modifications of catalytic residues.
Avidin and its bacterial analogue streptavidin share many similar
biochemical and structural properties, including their remarkable affinity toward the vitamin biotin (1, 2). The tremendously high
affinity between the proteins and their ligand has been exploited as a
powerful tool in numerous biotechnological applications (3, 4).
Despite differences in the primary structure of the two proteins
(~30% identity and 40% overall similarity) both have strikingly similar tertiary In contrast to the latter structural and functional similarities, the
two proteins differ in many other properties (2). One of the intriguing
differences between avidin and streptavidin lies in their propensity to
promote the hydrolysis of selected biotinyl ester derivatives (12).
Specifically, avidin was found to enhance the hydrolysis of biotinyl
p-nitrophenyl ester
(BNP),1 whereas streptavidin
was found to strongly protect the same biotin derivative from
hydrolysis. It was also discovered that upon chemical modification of
lysine residues in avidin, the hydrolysis of BNP is lost (12). In this
context, we have recently determined the crystal structures of avidin
and streptavidin in complex with biotinyl p-nitroanilide
(BNA), the stable amide analogue of BNP (12). The structures of the
avidin and streptavidin complexes with BNA revealed the structural and
chemical factors that appear to contribute to the observed differences
in hydrolytic potential toward BNP.
Three main determinants were noted that could account for the
hydrolytic activity in avidin versus the protection afforded by streptavidin. (i) The disordered conformation of the L3,4 loop in
avidin, which would permit solvent accessibility to the ester group of
BNP as opposed to the closed conformation of the loop in streptavidin
(similar to that in the streptavidin-biotin complex), in which the
ligand is almost completely buried (Fig.
1). It is also noteworthy that the L3,4
loop in avidin is three residues larger than that of streptavidin, and
its disposition in avidin is more susceptible toward derivatized biotin
ligands, thus resulting in the observed disordered conformation (13).
(ii) Arg-114 of avidin, which protrudes from the
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-barrel topology and homo-tetrameric quaternary arrangement. Both proteins contain four biotin-binding sites wherein the interacting residues are remarkably similar. In addition to the
binding residues, the contribution of a critical tryptophan (Trp-110 and Trp-120 in avidin and streptavidin, respectively), donated from an adjacent monomer, plays a pivotal role both in biotin
binding and in the stability of the tetrameric structure (5-7). Avidin
and streptavidin in their apo forms, include a disordered L3,4 loop
(i.e. the loop connecting strands
3 and
4), thus
exposing the biotin-binding site. Upon biotin binding, the
"lid-like" loop adopts an ordered and closed conformation, thereby
burying the biotin molecule in the binding site (8-11) and rendering
the ligand almost completely inaccessible to the solvent.
8 strand, repels
the BNP into a conformation that promotes its interaction with Lys-111
from an adjacent monomer. In streptavidin, the homologous position is
occupied by a smaller residue, Leu-124, that allows the BNP ligand to
adopt an alternative conformation that precludes interaction with
Lys-121 (Fig. 2). (iii) In avidin, the
formation of a hydrogen bond between the nitro group of BNP and Lys-111
increases the electron-withdrawing properties of the
p-nitrophenyl moiety, thus enhancing its leaving-group
properties and promoting hydrolysis under conditions of relatively low
pH values. In streptavidin, however, the BNP acquires a different
conformation that prevents interaction with the critical lysine residue
(Fig. 2).
View larger version (33K):
[in a new window]
Fig. 1.
Tube representation of the tertiary
structures of avidin and streptavidin complexes with BNA (shown in
black). The L3,4 loop in streptavidin is in the
closed and ordered conformation, whereas in avidin the loop is
disordered (indicated by arrows). The
p-nitroanilide moiety of BNA maintains different
conformations in the complexes.
View larger version (49K):
[in a new window]
Fig. 2.
Superposition of the avidin- and
streptavidin-BNA complexes, showing the binding site region and the 1,2 interface. Both monomers (Mon1 and Mon2) of avidin and
streptavidin are shown in cyan and magenta
respectively. The avidin side chains of Lys-111, Arg-114, and the BNA
ligand of the complex are shown in blue, whereas the
respective streptavidin-based Lys-121, Leu-124, and BNA are shown in
red. Arg-114 in avidin protruding from 8 repels
the p-nitroanilide segment of BNA to adopt a conformation
that facilitates hydrogen bond formation between the nitro group and
Lys-111. Conversely, in streptavidin Leu-124 permits a different BNA
conformation, wherein the nitro group is distant from Lys-121.
Based on the structural and biochemical differences between the two proteins, we designed a series of streptavidin mutations. Our main objectives were to evaluate the structural factors that result in the pseudo-catalytic properties in avidin and to convert streptavidin from a protector of the BNP ligand to one that enhances its hydrolysis. Consequently, Leu-124 in streptavidin was converted to Arg (mutant M1), and the relatively shorter L3,4 loop (residues 48-52) of streptavidin was replaced to emulate that (residues 38-45) of avidin (mutant M2). A third construct was generated to contain both modifications (i.e. the point mutation and the L3,4 loop exchange; mutant M3).
In this study, we thus elected to mutate streptavidin in a manner that
would both sterically divert the substrate into the correct
conformation for the hydrolytic reaction to occur and expose the
substrate to the solvent. Importantly, throughout the design of the
three mutations, the purported residue (Lys-121 in streptavidin) that
drives the hydrolysis was not subjected to mutation. This work is the
first instance in which rational mutagenesis of a protein has been
employed for steric diversion of a substrate in a binding site to
attain a preferred orientation that favors hydrolysis. This strategy
represents an alternative approach for protein modification in the
design of enzymes (14-16).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Construction and Expression of Mutants-- A pET-21a plasmid, containing an insert encoding for core streptavidin with favorable codon usage for expression in Escherichia coli, was kindly provided by P. Stayton. Site-directed mutagenesis of Leu-124 to Arg (mutation M1), was performed with primers P1 and P2 (Table I) using the QuikChange kit (Stratagene) according to the manufacturer's instructions. The core streptavidin was used as a template for the exchange of the L3,4 loop of avidin. The desired exchange of the L3,4 loop (mutation M2) was achieved by PCR using two separate fragments: fragment 1 was formed by primers P3 and P6, and fragment 2 was produced using primers P4 and P5 (Table I) using the core streptavidin as a template. The combination of the L124R mutation of streptavidin (mutation M1 as template), combined with the primers used for modifying the L3,4 loop, generated the double mutant (mutation M3), in which the L124R mutation was obtained in combination with the modified L3,4 loop.
|
Streptavidin mutants were expressed in E. coli using the
pET-21a expression vector (Novagen) according to the protocol
essentially as reported previously (17). Starter BL21 cells,
transfected with the various constructs, were grown in 2×
yeast-tryptone media at 37 °C until an
A600 of 0.6-0.8 was attained. Expression
was induced with 0.4 mM isopropyl
-D-thiogalactopyranoside for 6-8 h at 37 °C,
after which the cells were harvested.
Isolation and Purification of Streptavidin Mutants-- The cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.02% sodium azide) to 1/20 of the original culture volume. After mechanical disruption of the cells using a microfluidizer (model M-110 EHIS, Microrofluidics Corp., Newton, MA), the lysate was centrifuged at 12,000 rpm for 20 min. For the isolation of the inclusion bodies, the insoluble fraction was washed once with 50 mM Tris-HCl (pH 8), 10 mM EDTA, 1.5 M NaCl, 1 mM PMSF, and 0.5% Triton X-100 and four times in the same buffer solution without Triton X-100. For the L124R mutation, inclusion bodies were dissolved in 6 M guanidine hydrochloride (pH 1.5) and incubated for 1 h at 4 °C. The suspension was then centrifuged, and the supernatant fluids were dialyzed against 2 liters of dialysis buffer containing 50 mM Tris-HCl (pH 8), 150 mM NaCl, 10 mM EDTA, 0.1 M PMSF, and 0.5 mM benzamidine for 24 h with two changes of dialysis buffer. The protein solution was centrifuged at 12,000 rpm for 30 min to remove the excess of pelleted unfolded protein. For the sL3,4a and the L124R+sL3,4a mutants, the pellets of inclusion bodies were resuspended in 0.1 M NaH2PO4, 6 M guanidine hydrochloride (pH 1.5), and 3 mM 1,4-dithiothreitol. After 1 h of incubation, the solubilized protein was dialyzed for 12 h at 4 °C against 2 liters of refolding buffer containing 0.2 M NaHCO3 (pH 8), 250 mM NaCl, and 10% glycerol. The unfolded protein was removed by centrifugation at 18,000 × g for 30 min, and the solution fraction was further dialyzed against two liters of the same buffer, initially with the addition of 5% glycerol and later without glycerol. NaCl was added to the mutant protein solutions to a final concentration of 0.5 M, and the pH value was adjusted to 10 with 1 N NaOH. Affinity purification using iminobiotin-agarose was performed according to the procedure recommended by the manufacturer (Pierce) (18, 19). Samples containing the desired streptavidin mutants were eluted from the iminobiotin column with 0.1 M acetic acid (pH 2.9) concentrated to 0.5 mg/ml protein and assayed immediately.
Hydrolysis Assay--
BNP was dissolved in dimethylformamide (7 nmol per 10 µl) and added to a solution containing 16 nmol of subunit
mutant in 0.5 ml. The assay for BNP hydrolysis was conducted as
previously described (12, 20) with some modifications. Core
streptavidin and avidin were also assayed for comparison of the
activity of the given mutant. Protein solutions were incubated for 15 min at 23 °C. The pH value was initially adjusted to the approximate value by adding either 1 M phosphate buffer or 1 M Na2CO3, and the solution was then
titrated with 5 N NaOH to the desired pH value. Hydrolysis
was assayed versus time at different pH values and monitored
by the release of p-nitrophenol at
A410. The hydrolysis assays were performed at pH
values ranging between 6.5 and 10.5, and the concentration of
p-nitrophenol was measured as a function of time.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The extent of BNP hydrolysis was examined at several pH values.
The results emphasize the differences in the pseudocatalytic properties
of the different mutants compared with those observed for the avidin
and streptavidin molecules (Fig. 3). At
pH values below 9.0, the results revealed but a limited effect on
hydrolytic activity for the L124R point mutant M1, and the protective
behavior of streptavidin is preserved. As the pH is raised, the
hydrolytic activity for M1 increases slightly relative to that of
streptavidin until pH 10.5, whereby the hydrolysis of BNP by mutant M1
is increased drastically to emulate that of avidin (Fig. 3).
|
At pH values below 8.0, mutant M2 still exhibits a protective effect vis-à-vis BNP hydrolysis, although under more basic conditions the activity of this mutant is dramatically increased to levels of hydrolysis similar to those observed for avidin. The level of hydrolytic activity for the double mutation (M3) drops sharply at pH below 7.5 compared with that of avidin, which still exhibits substantial hydrolysis. The observed hydrolysis by avidin below pH 7 represents a minimal value since the pK of the p-nitrophenyl leaving group is around 7. Above pH 7.5, the extent of BNP hydrolysis exhibited by M3 is even higher than that of avidin.
The rates of hydrolysis were examined at pH 10 and 10.5 (Fig.
4), and the results confirmed the
above-described tendencies. Streptavidin protects the hydrolysis of BNP
even after overnight incubation. The point mutation M1 is only slightly
more active than streptavidin at pH 10 (Fig. 4), but its activity
increases drastically at pH 10.5 to values comparable to avidin. The
hydrolytic activity of the loop mutation M2 is markedly higher than
that of M1 at pH 10, and the course of hydrolysis increases gradually and reaches a maximum after overnight incubation, whereby the final
values observed are approximate those measured for avidin. Although the
extent of BNP hydrolysis by M2 indeed resembles that of avidin, the
rate of reaction is much slower. The initial rate of hydrolysis for the
combined mutant M3 is much higher at pH 10 than that of M2 but lower
than that of avidin. At later stages of hydrolysis, the extent of
hydrolysis by M3 is very similar to the level observed for avidin.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although the structures of the avidin and streptavidin complexes with BNA have been determined and analyzed, the factors determining the pseudo-catalytic properties of avidin have yet to be verified. Lys-111 in avidin plays a direct and essential role in the hydrolysis reaction. The amine side chain forms a hydrogen bond with the nitro group of BNP thus enhancing the electron-withdrawing properties of the nitro group and subsequent leaving-group properties of the p-nitrophenyl moiety.
The crystal structures also revealed two additional factors in avidin, which are lacking in streptavidin but play an indirect role in the hydrolysis reaction. The L3,4 loop of avidin exhibits higher flexibility than that of streptavidin by adopting a disordered conformation in many of the complexes with biotin analogues (13). Conversely, in many of the streptavidin complexes with the same analogues, this loop retains an ordered "consensus" conformation (12). The disordered L3,4 loop of avidin exposes the p-nitrophenyl moiety of BNP to the solvent and thus permits nucleophilic attack on the ester bond. In streptavidin, however, the closed conformation of the L3,4 loop (Fig. 1) serves to bury the BNP molecule in the binding site, thus rendering the ligand completely inaccessible to solvent. In addition to solvent accessibility of BNP in avidin, Arg-124 shoves the p-nitrophenyl group into an orientation that allows its interaction with Lys-111 from an adjacent avidin monomer.
The assay of hydrolytic activity for the three streptavidin mutants revealed that both the lid-like L3,4 loop and Arg-124 indeed play an important role in promoting the hydrolysis reaction as deduced from the x-ray structures. The results also show that each of the two factors (the L3,4 loop and Arg-124) contributes differently to the course of the reaction. In this context, under moderate alkaline conditions, the hydrolytic activity of mutant M1 is only marginally higher than that of streptavidin, which protects the ligand from the reaction. This modest increase in hydrolytic activity, displayed by M1 under alkaline conditions, may imply that a diversion of the p-nitrophenyl group of the ligand and its plausible interaction with the lysine residue from an adjacent monomer is not the crucial factor that drives BNP hydrolysis.
On the other hand, the exchange of the lid-like loop of streptavidin (mutant M2) appears to enhance drastically the hydrolytic properties of streptavidin. M2 contains a larger L3,4 loop, which is probably flexible and displays a higher level of disorder upon ligand binding. M2 is thus active at relatively low pH (below 8.5), although the observed extent of hydrolysis is lower than that of avidin (Fig. 2). It is thus expected that the L3,4 loop is disordered upon BNP binding, thereby exposing the ligand to the solvent and facilitating nucleophilic attack on the ester bond. Consequently, the disordered conformation of L3,4 is only one of the essential elements that promotes the hydrolysis reaction. The enhanced hydrolysis reaction also requires facile interaction of the nitro group of BNP with the lysine residue from the adjacent monomer. In mutant M2, the p-nitrophenyl moiety of BNP is unconfined as in avidin and is thus free to maintain alternative conformations, some of which may indeed direct the nitro group toward the locale of the reactive lysine. The conformational freedom of the p-nitrophenyl group, however, may also explain the lower rate of hydrolysis observed by this mutant (Fig. 4) since, at any given moment, only a fraction of ligand molecules would be in a conformation (Fig. 2) that would favor interaction with the essential lysine residue.
Supplementing the characteristics of M2 with those of M1 (mutant M3) markedly increases the catalytic activity at pH 8 and higher (Figs. 3 and 4), similar to that observed for avidin. The increased activity of the double mutant relative to M2 implies that disorder in the L3,4 loop indeed promotes hydrolysis by water. Moreover, the steric diversion of the p-nitrophenyl group by Arg-124 toward Lys-121 is also important for further enhancement of the reaction and for lowering the pH of hydrolysis, which results from the formation of a hydrogen bond.
In this study, we examined experimentally our previously reported
structure-based hypotheses regarding the main determinants for
pseudo-catalytic activity of egg-white avidin. Based on the x-ray
structures of avidin and streptavidin complexed with BNA, we designed a
functionally active hydrolytic site in streptavidin. In doing so, we
succeeded in converting the streptavidin binding site from its
protection of the BNP ligand from pseudo-enzymatic hydrolysis to a
strong promoter of hydrolysis. The present study demonstrates clearly
that if the structure and mode of catalytic action of a protein is
known, the structural elements responsible for catalysis can be
transferred to a structurally similar but non-catalytic protein. In
this context, local alterations (e.g. point mutations or
major modifications in loop regions) are permissible, while the
scaffold (i.e. tertiary structure) of the protein must remain intact. Such an approach, in which catalytic properties have
been induced in a binding protein, has only been attempted successfully
in the past for antibodies (21-23). In the present study, we have now
demonstrated that catalytic properties can also be incorporated into
other protein systems.
![]() |
ACKNOWLEDGEMENTS |
---|
We would like to thank P. Stayton (University of Washington) for providing the gift of the plasmid containing the core streptavidin insert.
![]() |
FOOTNOTES |
---|
* This work was supported in part by the Israeli Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 972-2-658-6894; Fax: 972-2-658-5793; E-mail: oded.livnah@huji.ac.il.
Published, JBC Papers in Press, December 18, 2002, DOI 10.1074/jbc.M209983200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: BNP, biotinyl p-nitrophenyl ester; BNA, biotinyl p-nitroanilide; PMSF, phenylmethylsulfonyl fluoride.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Green, N. M. (1975) Adv. Protein. Chem. 29, 85-133[Medline] [Order article via Infotrieve] |
2. | Green, N. M. (1990) Methods Enzymol. 184, 51-67[Medline] [Order article via Infotrieve] |
3. | Wilchek, M., and Bayer, E. A. (1990) Methods Enzymol. 184, 5-13[Medline] [Order article via Infotrieve] |
4. | Bayer, E. A., and Wilchek, M. (1990) J. Chromatogr. 510, 3-11[CrossRef][Medline] [Order article via Infotrieve] |
5. | Laitinen, O. H., Airenne, K. J., Marttila, A. T., Kulik, T., Porkka, E., Bayer, E. A., Wilchek, M., and Kulomaa, M. S. (1999) FEBS Lett. 461, 52-58[CrossRef][Medline] [Order article via Infotrieve] |
6. | Freitag, S., Le, Trong, I., Chilkoti, A., Klumb, L. A., Stayton, P. S., and Stenkamp, R. E. (1998) J. Mol. Biol. 279, 211-221[CrossRef][Medline] [Order article via Infotrieve] |
7. |
Sano, T.,
Vajda, S.,
Smith, C. L.,
and Cantor, C. R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6153-6158 |
8. | Livnah, O., Bayer, E. A., Wilchek, M., and Sussman, J. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5076-5080[Abstract] |
9. |
Korndorfer, I. P.,
and Skerra, A.
(2002)
Protein Sci.
11,
883-893 |
10. | Hendrickson, W. A., Pähler, A., Smith, J. L., Satow, Y., Merritt, E. A., and Phizackerley, R. P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2190-2194[Abstract] |
11. | Weber, P. C., Ohlendorf, D. H., Wendoloski, J. J., and Salemme, F. R. (1989) Science 243, 85-88[Medline] [Order article via Infotrieve] |
12. |
Huberman, T.,
Eisenberg-Domovich, Y.,
Gitlin, G.,
Kulik, T.,
Bayer, E. A.,
Wilchek, M.,
and Livnah, O.
(2001)
J. Biol. Chem.
276,
32031-32039 |
13. |
Pazy, Y.,
Kulik, T.,
Bayer, E. A.,
Wilchek, M.,
and Livnah, O.
(2002)
J. Biol. Chem.
277,
30892-30900 |
14. | Altamirano, M. M., Blackburn, J. M., Aguayo, C., and Fersht, A. R. (2000) Nature 403, 617-622[CrossRef][Medline] [Order article via Infotrieve] |
15. | Davies, R. R., and Distefano, M. M. (1997) J. Am. Chem. Soc. 119, 11643-11652[CrossRef] |
16. | Imperiali, B., and Roy, R. S. (1994) J. Am. Chem. Soc. 116, 12083-12084 |
17. | Chilkoti, A., Tan, P. H., and Stayton, P. S. (1995) Proc. Natl. Acad. Sci. US 92, 1754-1758[Abstract] |
18. | Gitlin, G., Bayer, E. A., and Wilchek, M. (1987) Biochem. J. 242, 923-926[Medline] [Order article via Infotrieve] |
19. | Hoffmann, K., Wood, S. W., Brinton, C. C., Montibeller, J. A., and Finn, F. M. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 4666-4668[Abstract] |
20. | Wilchek, M., Gitlin, G., Bayer, E. A., and Viswanath, T. (1988) Biochemistry 27, 3099 |
21. | Pollack, S. J., and Schultz, P. G. (1989) J. Am. Chem. Soc. 111, 1929-1931 |
22. | Schultz, P. G., and Lerner, R. A. (1995) Science 269, 1835-1842[Medline] [Order article via Infotrieve] |
23. | Schultz, P. G., and Lerner, R. A. (2002) Nature 418, 485[CrossRef][Medline] [Order article via Infotrieve] |